Skip to content

Caroline Copeland

2 papers in the library · 2 citations · publishing 2025-2026

Papers

Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report.

Journal of psychopharmacology (Oxford, England) July 1, 2025 John Martin Corkery, Caroline Copeland, Fabrizio Schifano 2 citations

Diarylethylamine drugs, including diphenidine and methoxyphenidine (MXP), are dissociative substances with strong addictive potential. A systematic review of global mortality data found 48 deaths involving these drugs, with 37 occurring in the UK between 2014 and 2019. Most decedents were male (91%), White (95%), with a mean age of 37.2 years. Deaths were primarily accidental (89%) from acute drug toxicity (92%), often involving polysubstance poisoning with opioids, benzodiazepines, or stimulants. One-third of deaths involved MXP or diphenidine alone, suggesting these molecules are relatively toxic. Although diarylethylamine deaths are rare, these substances remain available, indicating ongoing risk.

Ketamine: reclassification alone will not reduce harms

BMJ February 3, 2026 Adam Winstock, David J Nutt, Caroline Copeland

Reclassifying ketamine without accompanying public health measures would be a symbolic action rather than an effective strategy for reducing harm, according to the authors. They argue that regulatory changes alone are insufficient and must be paired with broader public health interventions to meaningfully address risks associated with ketamine use.